Quatramer™ encapsulation of dual-targeted PI3-Kδ/HDAC6 inhibitor, HSB-510, suppresses growth of breast cancer.

"data s1: supporting information click here for additional data file."

"CONFLICT OF INTEREST STATEMENT Harpal Singh and Surender Kharbanda are members of the Scientific Advisory Board of Hillstream BioPharma Inc. Surender Kharbanda is an equity holder in Hillstream BioPharma. Harpal Singh is a consultant to Nanogen Pvt Ltd., New Delhi, India. Other authors have no potential conflicts of interest."

"Sachchidanand Tiwari acknowledges IIT Delhi and MHRD for fellowship support. We are grateful to Prof. Neetu Singh and her students, Dr. Sahil Malhotra and Ms. Shreemoyee De, for their support in FACS studies and animal studies. We thank Mr. Anil Pandey from CBME, IIT Delhi, for his guidance in animal experiments. We acknowledge Prof Sujata Mohanty and her students, Dr. Manu Dalela and Mr. E Pranshu Rao from AIIMS, New Delhi, for their guidance and support in animal imaging studies. Sachchidanand Tiwari, Ashish Thakur, Gregory J. Tawa, Gurmit Grewal, Surender Kharbanda, and Harpal Singh are inventors on a patent application that covers the technology discussed in the manuscript."